AmMax Bio Announces First Patient Dosed in Phase IIa Study Evaluating AMB-066 in Patients with Colorectal Cancer Minimal Residual Disease

0
23
AmMax Bio, Inc. announced the dosing of the first patient in its Phase IIa study evaluating AMB-066 for the treatment of patients with colorectal cancer minimal residual disease.
[AmMax Bio, Inc.]
Press Release